Description
UPERIO is indicated for the treatment of heart failure (NYHA class II-IV) in patients with reduced ejection fraction (LVEF ≤40%). The target dose of UPERIO is 200 mg twice daily. The recommended starting dose of UPERIO is 100 mg twice daily.
Additional information
| brand | Novartis Pharmaceuticals |
|---|
